

Diabetes Drugs For Stiff Heart Failure

Written by The Life Science Feed Editorial Team · Published 1 June 2026 · Edited by James Carter

KEY TAKEAWAYS

- EMPEROR-Preserved and DELIVER: both SGLT2 inhibitors significantly reduce HF hospitalisation in HFpEF - first drugs to do so after 20 years of failed trials
- FINEARTS-HF 2024: finerenone (non-steroidal MRA) also reduces worsening HF events in HFmrEF/HFpEF
- HFpEF driven by inflammation, fibrosis, metabolic comorbidities - not neurohormonal activation; explains why earlier drug classes failed
- Structured HFpEF diagnosis using HFA-PEFF or H2FPEF algorithms is now clinically important as effective treatments exist

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Anker SD et al. EMPEROR-Preserved. N Engl J Med. 2021;385:1451-1461
2. Solomon SD et al. DELIVER. N Engl J Med. 2022;387:1089-1098
3. Lam CSP et al. EMPEROR-DELIVER pooled. Nat Med. 2022;28:2726-2734
4. Solomon SD et al. FINEARTS-HF. N Engl J Med. 2024
5. McDonagh TA et al. 2023 Focused Update ESC HF Guidelines. Eur Heart J. 2023

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com